Premium
Studies of the V94M‐substituted human UDPgalactose‐4‐epimerase enzyme associated with generalized epimerase‐deficiency galactosaemia
Author(s) -
Wohlers T. M.,
FridovichKeil J. L.
Publication year - 2000
Publication title -
journal of inherited metabolic disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.462
H-Index - 102
eISSN - 1573-2665
pISSN - 0141-8955
DOI - 10.1023/a:1005682913784
Subject(s) - galactosemia , enzyme , biology , galactose , biochemistry , mutation , mutant , genetics , allele , gene
Abstract Impairment of the human enzyme UDPgalactose 4‐epimerase (hGALE) results in epimerase‐deficiency galactosaemia, an inborn error of metabolism with variable biochemical presentation and clinical outcomes reported to range from benign to severe. Molecular studies of the hGALE loci from patients with epimerase deficiency reveal significant allelic heterogeneity, raising the possibility that variable genotypes may constitute at least one factor contributing to the biochemical and clinical heterogeneity observed. Previously we have identified a single substitution mutation, V94M, present in the homozygous state in all patients genotyped with the severe, generalized form of epimerase‐deficiency galactosaemia. We report here further studies of the V94M‐hGALE enzyme, overexpressed and purified from a null‐background yeast expression system. Our results demonstrate that the mutant protein is impaired relative to the wild‐type enzyme predominantly at the level of V max rather than of K m . Studies using UDP‐ N ‐acetylgalactosamine as a competitor of UDPgalactose further demonstrate that the K m values for these two substrates vary by less than a factor of 3 for both the wild‐type and mutant proteins. Finally, we have explored the impact of the V94M substitution on susceptibility of yeast expressing human GALE to galactose toxicity, including changes in the levels of galactose 1‐phosphate (gal‐1‐P) accumulated in these cells at different times following exposure to galactose. We have observed an inverse correlation between the level of GALE activity expressed in a given culture and the degree of galactose toxicity observed. We have further observed an inverse correlation between the level of GALE activity expressed in a culture and the concentration of gal‐1‐P accumulated in the cells. These data support the hypothesis that elevated levels of gal‐1‐P may underlie the observed toxicity. They further raise the intriguing possibility that yeast may provide a valuable model not only for assessing the impact of given patient mutations on hGALE function, but also for exploring the metabolic imbalance resulting from impaired activity of GALE in living cells.